Pharmaceutical News and Articles

8 Million U.S. Individuals Estimated to Use Magic Mushrooms in Past Year

An estimated 8 million Americans have used magic mushrooms (psilocybin) in the past year, according to a research letter published online April 21 in The Americ

Problem-Solving Strategy Boosts Mental Health in Young Adults With Cancer

A problem-solving skills training intervention is effective at reducing depression and anxiety in young adults newly diagnosed with cancer, according to a study

DDW: Combination Therapy Shows Efficacy for Crohn Disease, Ulcerative Colitis

For patients with Crohn disease and ulcerative colitis (UC), a fixed-dose co-antibody therapy targeting interleukin-23p19 subunit and tumor necrosis factor- , J

Prenatal Exposure to Benzodiazepines, Z-Hypnotics Not Linked to Psychiatric Disorders in Offspring

Prenatal exposure to benzodiazepines or Z-hypnotics is not associated with an increased risk for psychiatric disorders in offspring when accounting for familial

Medications Affecting Cognition More Often Prescribed for Seniors in Nonoffice Settings

Prescriptions for medications affecting cognition in older adults, such as antipsychotics, are disproportionately more likely to be initiated from settings othe

Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now

TUESDAY, May 5, 2026 U.S. Supreme Court Justice Samuel Alito Jr. issued an order Monday that allows patients to continue accessing abortion pill, mifepristone,

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

OSAKA, Japan and CAMBRIDGE, Massachusetts, May 4, 2026 Takeda (TSE 4502 NYSE TAK) today announced that TAK-881-3001, a pivotal Phase 2 3 clinical trial in patie

FDA Approves Langlara (insulin glargine-aldy), an Interchangeable Biosimilar to Lantus

ADMA Biologics Announces FDA Approval to Expand the Label for Asceniv to Include Pediatric Immune Compromised Patients Two Years of Age and Older

FDA Approves Dupixent for Chronic Spontaneous Urticaria in Young Children

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (C